Health Care [ 9/12 ] | Biotechnology [ 42/73 ]
NYSE MKT | Common Stock
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.
The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials.
The company was founded in 2015 and is headquartered in Ness Ziona, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 25 | -0.19 Decreased by -396.88% | -0.26 Increased by +26.92% |
| May 19, 25 | 0.33 Increased by +376.38% | -0.30 Increased by +210.00% |
| Mar 25, 25 | -1.15 Decreased by -43.75% | -1.09 Decreased by -5.02% |
| Nov 12, 24 | -0.67 Decreased by -413.15% | -0.40 Decreased by -66.77% |
| Aug 15, 24 | 0.06 Decreased by -46.67% | -0.87 Increased by +107.38% |
| May 21, 24 | -0.12 Increased by +40.30% | -1.15 Increased by +89.62% |
| Dec 31, 23 | -0.80 Decreased by -300.00% | -1.10 Increased by +27.27% |
| Nov 14, 23 | -0.13 Increased by +43.48% | -0.12 Decreased by -13.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Increased by +100.00% | -6.04 M Decreased by -235.03% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Increased by +100.00% | -7.66 M Increased by +55.80% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 172.00 K Increased by +N/A% | -14.51 M Decreased by -164.31% | Decreased by -8.44 K% Decreased by N/A% |
| Sep 30, 24 | -84.00 K Increased by +5.62% | -9.64 M Decreased by -2.42 K% | Increased by +11.48 K% Increased by +2.57 K% |
| Jun 30, 24 | -2.02 M Decreased by -2.14 K% | 4.47 M Increased by +169.74% | Decreased by -221.67% Decreased by -103.11% |
| Mar 31, 24 | -88.00 K Increased by +3.30% | -17.33 M Decreased by -172.39% | Increased by +19.69 K% Increased by +181.68% |
| Dec 31, 23 | 0.00 Increased by +100.00% | -5.49 M Increased by +6.71% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | -89.00 K Decreased by -71.15% | -382.00 K Increased by +94.37% | Increased by +429.21% Decreased by -96.71% |